Free Trial

Instil Bio (TIL) Competitors

Instil Bio logo
$34.23 -3.28 (-8.74%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$34.20 -0.02 (-0.07%)
As of 06/13/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TIL vs. PRAX, ARDX, LENZ, OCS, ZYME, NTLA, NUVB, PHAR, IMNM, and AVBP

Should you be buying Instil Bio stock or one of its competitors? The main competitors of Instil Bio include Praxis Precision Medicines (PRAX), Ardelyx (ARDX), LENZ Therapeutics (LENZ), Oculis (OCS), Zymeworks (ZYME), Intellia Therapeutics (NTLA), Nuvation Bio (NUVB), Pharming Group (PHAR), Immunome (IMNM), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry.

Instil Bio vs. Its Competitors

Instil Bio (NASDAQ:TIL) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, community ranking, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 47.2% of Instil Bio shares are held by insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Praxis Precision Medicines has higher revenue and earnings than Instil Bio. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Instil BioN/AN/A-$156.09M-$11.97-2.86
Praxis Precision Medicines$8.12M111.10-$123.28M-$10.72-4.13

Instil Bio currently has a consensus target price of $119.00, indicating a potential upside of 247.65%. Praxis Precision Medicines has a consensus target price of $109.90, indicating a potential upside of 148.08%. Given Instil Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Instil Bio is more favorable than Praxis Precision Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Instil Bio
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00
Praxis Precision Medicines
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80

Instil Bio has a net margin of 0.00% compared to Praxis Precision Medicines' net margin of -9,409.22%. Instil Bio's return on equity of -37.44% beat Praxis Precision Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Instil BioN/A -37.44% -25.08%
Praxis Precision Medicines -9,409.22%-54.86%-50.52%

In the previous week, Praxis Precision Medicines had 3 more articles in the media than Instil Bio. MarketBeat recorded 6 mentions for Praxis Precision Medicines and 3 mentions for Instil Bio. Praxis Precision Medicines' average media sentiment score of 0.30 beat Instil Bio's score of 0.30 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Instil Bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Praxis Precision Medicines
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Instil Bio received 49 more outperform votes than Praxis Precision Medicines when rated by MarketBeat users. However, 75.34% of users gave Praxis Precision Medicines an outperform vote while only 50.49% of users gave Instil Bio an outperform vote.

CompanyUnderperformOutperform
Instil BioOutperform Votes
104
50.49%
Underperform Votes
102
49.51%
Praxis Precision MedicinesOutperform Votes
55
75.34%
Underperform Votes
18
24.66%

Instil Bio has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.6, suggesting that its share price is 160% more volatile than the S&P 500.

Summary

Instil Bio and Praxis Precision Medicines tied by winning 9 of the 18 factors compared between the two stocks.

Get Instil Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TIL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TIL vs. The Competition

MetricInstil BioBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$224.52M$3.09B$5.57B$8.50B
Dividend YieldN/A1.56%5.28%4.16%
P/E Ratio-2.9632.6326.6319.64
Price / SalesN/A455.18407.99152.17
Price / CashN/A168.6838.2534.64
Price / Book0.993.366.964.60
Net Income-$156.09M-$72.35M$3.23B$248.06M
7 Day Performance4.07%0.30%-1.13%-0.94%
1 Month Performance157.56%16.40%8.59%3.52%
1 Year Performance227.87%-15.52%33.63%14.02%

Instil Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TIL
Instil Bio
2.996 of 5 stars
$34.23
-8.7%
$119.00
+247.6%
+226.0%$224.52MN/A-2.96410Short Interest ↑
Gap Up
PRAX
Praxis Precision Medicines
2.7396 of 5 stars
$44.51
-0.1%
$109.90
+146.9%
+10.6%$906.62M$8.12M-4.32110Analyst Forecast
Gap Down
ARDX
Ardelyx
3.9268 of 5 stars
$3.76
+2.2%
$10.39
+176.3%
-44.5%$899.60M$361.71M-23.5090Positive News
Insider Trade
Analyst Revision
LENZ
LENZ Therapeutics
1.6484 of 5 stars
$31.22
-2.3%
$46.60
+49.3%
+55.7%$899.55MN/A-17.64110High Trading Volume
OCS
Oculis
1.7527 of 5 stars
$19.92
flat
$31.50
+58.1%
+60.1%$869.75M$980K-10.322Positive News
Short Interest ↑
ZYME
Zymeworks
1.8536 of 5 stars
$12.45
-1.2%
$21.00
+68.7%
+39.1%$866.23M$93.38M-8.30460Positive News
Gap Down
NTLA
Intellia Therapeutics
4.5921 of 5 stars
$8.28
+2.3%
$34.95
+322.1%
-68.0%$857.67M$45.57M-1.52600Analyst Revision
Gap Down
High Trading Volume
NUVB
Nuvation Bio
2.9534 of 5 stars
$2.51
+1.2%
$7.83
+212.1%
-42.3%$854.06M$10.96M-1.1660News Coverage
Analyst Forecast
High Trading Volume
PHAR
Pharming Group
2.1795 of 5 stars
$11.81
-0.4%
$30.00
+154.0%
+26.4%$806.69M$320.71M-45.42280News Coverage
Short Interest ↑
IMNM
Immunome
1.6337 of 5 stars
$9.27
+1.5%
$23.33
+151.7%
-42.6%$806.60M$10.94M-1.1440News Coverage
Positive News
Gap Down
AVBP
ArriVent BioPharma
1.4705 of 5 stars
$23.60
+0.3%
$39.29
+66.5%
+23.6%$804.69MN/A-6.2640Positive News

Related Companies and Tools


This page (NASDAQ:TIL) was last updated on 6/14/2025 by MarketBeat.com Staff
From Our Partners